We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

CPU:ASXComputershare Limited Analysis

Data as of 2026-06-17 - not real-time

A$36.55

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Computershare (CPU.AX) is trading at AUD 36.55, roughly 2% above its DCF‑derived fair value of AUD 17.80, indicating a significant premium. The stock’s trailing PE of 25.2 sits well above the industry average of 17.1, reinforcing the overvaluation signal. Technicals show the price comfortably above the 20‑day (34.94) and 50‑day (32.19) SMAs, and even the 200‑day SMA (33.49), suggesting recent bullish momentum. However, the RSI of 71.7 places the security in overbought territory, and a decreasing volume trend hints at waning buying pressure. The MACD line remains marginally bullish (1.30 vs signal 1.26) but the tiny histogram (+0.04) underscores limited upside momentum. Despite the price premium, the dividend yield of 3.04% with a 58% payout ratio is supported by robust operating cash flow of AUD 0.81 bn and a free cash flow conversion of over 80%.
The company delivers a strong ROE of 28.7% and a healthy gross margin of 28%, reflecting efficient operations. Debt‑to‑equity stands at 83%, yet the balance sheet is bolstered by AUD 1.12 bn of cash, keeping leverage manageable. Operating in the capital‑markets segment of Financial Services, CPU benefits from diversified geographic exposure across Asia, Europe, and North America, which mitigates single‑region shocks. Volatility remains elevated at 23.8% over the past 30 days, but a low beta of 0.34 indicates limited systematic risk relative to the market. Analyst consensus (11 contributors) rates the stock as a “buy” with a median target of AUD 35.17, slightly below the current price, implying limited upside. Consequently, the stock appears overvalued in the short run, but its dividend yield and resilient cash generation support a hold stance for medium‑term investors and a buy‑and‑hold case for long‑term income seekers.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • RSI in overbought zone suggests near‑term correction
  • Decreasing volume trend erodes momentum
  • Current price exceeds DCF fair value and analyst median target

Medium Term

1–3 years
Neutral
Model confidence: 7/10

Key Factors

  • Attractive dividend yield with sustainable payout
  • Strong ROE and cash flow underpin earnings stability
  • Valuation premium may compress but fundamentals remain solid

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Durable recurring revenue from global issuer services
  • Dividend provides steady income over time
  • High ROE and low beta support long‑term risk‑adjusted returns

Key Metrics & Analysis

Financial Health

Revenue Growth4.60%
Profit Margin18.81%
P/E Ratio25.2
ROE28.70%
ROA11.03%
Debt/Equity83.26
P/B Ratio6.6
Op. Cash FlowA$806.4M
Free Cash FlowA$687.0M
Industry P/E17.1

Technical Analysis

TrendNeutral
RSI71.7
SupportA$33.00
ResistanceA$37.29
MA 20A$34.94
MA 50A$32.19
MA 200A$33.49
MACDBullish
VolumeDecreasing
Fear & Greed Index92.3

Valuation

Fair ValueA$17.80
Target PriceA$35.78
Upside/Downside-2.11%
GradeOvervalued
TypeBlend
Dividend Yield3.04%

Risk Assessment

Beta0.34
Volatility23.81%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.